Galectin Therapeutics Inc.
Index- P/E- EPS (ttm)-0.52 Insider Own14.30% Shs Outstand59.35M Perf Week-1.54%
Market Cap74.83M Forward P/E- EPS next Y-0.54 Insider Trans0.01% Shs Float36.36M Perf Month-24.71%
Income-30.70M PEG- EPS next Q-0.14 Inst Own12.60% Short Float6.61% Perf Quarter-39.91%
Sales- P/S- EPS this Y-26.70% Inst Trans0.57% Short Ratio21.04 Perf Half Y-54.77%
Book/sh0.01 P/B128.00 EPS next Y-28.80% ROA-90.20% Target Price14.00 Perf Year-69.52%
Cash/sh0.68 P/C1.89 EPS next 5Y- ROE-321.30% 52W Range1.26 - 4.57 Perf YTD-38.16%
Dividend- P/FCF- EPS past 5Y7.30% ROI- 52W High-71.99% Beta1.66
Dividend %- Quick Ratio4.60 Sales past 5Y- Gross Margin- 52W Low1.59% ATR0.11
Employees9 Current Ratio4.60 Sales Q/Q- Oper. Margin- RSI (14)34.68 Volatility8.41% 7.51%
OptionableYes Debt/Eq72.50 EPS Q/Q11.50% Profit Margin- Rel Volume0.57 Prev Close1.35
ShortableYes LT Debt/Eq72.50 Earnings- Payout- Avg Volume114.16K Price1.28
Recom2.00 SMA20-14.47% SMA50-21.05% SMA200-49.43% Volume64,835 Change-5.19%
Aug-13-20Reiterated H.C. Wainwright Buy $9 → $12
Feb-13-19Initiated B. Riley FBR Buy $11
Dec-07-17Reiterated H.C. Wainwright Buy $6 → $10
Nov-28-17Reiterated H.C. Wainwright Buy $3.50 → $6
Oct-19-17Initiated ROTH Capital Buy
Mar-30-17Upgrade H.C. Wainwright Neutral → Buy $3.50
Oct-03-16Downgrade FBR & Co. Outperform → Mkt Perform $12 → $2
Sep-29-16Downgrade H.C. Wainwright Buy → Neutral $1.50
Sep-28-16Downgrade ROTH Capital Buy → Sell
Mar-28-16Resumed H.C. Wainwright Buy $8
Sep-21-15Initiated H.C. Wainwright Buy $7
Aug-01-14Downgrade Aegis Capital Buy → Hold
Jul-30-14Reiterated MLV & Co Buy $27 → $16
Jul-29-14Reiterated MLV & Co Buy $27 → $15
Apr-02-14Reiterated MLV & Co Buy $20 → $27
Feb-10-14Reiterated Aegis Capital Buy $16 → $32
Jan-09-14Reiterated Aegis Capital Buy $10 → $16
Dec-03-13Initiated MLV & Co Buy $20
Aug-19-13Reiterated Aegis Capital Buy $7 → $10
May-16-22 08:00AM  
May-11-22 11:20AM  
May-03-22 08:30AM  
Apr-15-22 07:20AM  
Apr-14-22 08:00AM  
Mar-31-22 08:00AM  
Jan-06-22 08:00AM  
Dec-21-21 08:00AM  
Dec-13-21 08:00AM  
Nov-15-21 08:00AM  
Nov-05-21 04:24PM  
Oct-27-21 08:00AM  
Oct-05-21 03:39PM  
Sep-21-21 08:00AM  
Sep-09-21 09:00AM  
Aug-30-21 08:00AM  
Aug-16-21 09:00AM  
Jul-30-21 04:28AM  
Jul-09-21 09:25AM  
Jun-13-21 11:23PM  
May-17-21 08:00AM  
Apr-27-21 09:28AM  
Apr-19-21 08:00AM  
Apr-15-21 09:00AM  
Apr-14-21 08:28AM  
Apr-13-21 07:01PM  
Apr-06-21 08:00AM  
Mar-31-21 08:00AM  
Mar-08-21 08:00AM  
Mar-04-21 08:00AM  
Jan-31-21 02:28AM  
Jan-19-21 11:15AM  
Dec-11-20 08:00AM  
Dec-04-20 04:17PM  
Dec-01-20 08:00AM  
Nov-09-20 08:00AM  
Nov-02-20 08:02AM  
Oct-12-20 08:11AM  
Oct-06-20 03:30PM  
Sep-29-20 12:00PM  
Sep-22-20 08:04AM  
Sep-10-20 08:00AM  
Sep-09-20 11:46AM  
Sep-02-20 08:00AM  
Aug-10-20 08:00AM  
Aug-03-20 12:48PM  
Jun-30-20 09:05AM  
Jun-04-20 09:48PM  
May-22-20 08:17AM  
May-11-20 08:00AM  
May-04-20 08:37AM  
Apr-30-20 09:00AM  
Apr-02-20 08:04AM  
Mar-16-20 08:00AM  
Feb-20-20 08:00AM  
Feb-05-20 04:11PM  
Feb-04-20 08:04AM  
Dec-20-19 06:38PM  
Dec-09-19 08:00AM  
Dec-05-19 12:06PM  
Nov-26-19 08:00AM  
Nov-18-19 04:10PM  
Nov-12-19 08:00AM  
Nov-11-19 09:47AM  
Nov-05-19 08:00AM  
Oct-28-19 08:39AM  
Sep-17-19 08:00AM  
Sep-11-19 10:13AM  
Aug-27-19 03:21PM  
Aug-09-19 08:00AM  
Aug-07-19 11:20AM  
Aug-06-19 10:51AM  
Aug-05-19 08:05AM  
May-28-19 09:05AM  
May-27-19 08:44AM  
May-23-19 05:30PM  
May-10-19 08:05AM  
Apr-15-19 08:00AM  
Apr-02-19 08:00AM  
Mar-22-19 10:19AM  
Mar-06-19 11:34AM  
Feb-26-19 07:25AM  
Feb-25-19 08:00AM  
Feb-13-19 03:36PM  
Feb-04-19 09:27AM  
Feb-01-19 10:07AM  
Galectin Therapeutics Inc., a clinical stage biopharmaceutical company, engages in the research and development of therapies for fibrotic, cancer, and other diseases. The company's lead product candidate is (GR-MD-02) belapectin galectin-3 inhibitor, a galactoarabino-rhamnogalacturonan polysaccharide polymer that is in Phase III clinical trial for the treatment of liver fibrosis associated with fatty liver disease and non-alcoholic steatohepatitis cirrhosis, as well as for the treatment of cancer. It also engages in developing GM-CT-01, which is in pre-clinical development stage for the treatment of cardiac and vascular fibrosis, as well as focuses on developing belapectin for the treatment of psoriasis, and lung and kidney fibrosis. The company, through its Galectin Sciences, LLC, which is a collaborative joint venture co-owned by SBH Sciences, Inc., to research and development of small organic molecule inhibitors of galectin-3 for oral administration. The company was formerly known as Pro-Pharmaceuticals, Inc. and changed its name to Galectin Therapeutics, Inc. in May 2011. Galectin Therapeutics Inc. was founded in 2000 and is based in Norcross, Georgia.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
FREEMAN KEVIN DDirectorApr 18Buy1.715,0008,55060,000Apr 18 03:59 PM
Zordani Richard A. Jr.DirectorApr 04Buy1.605,0008,02524,583Apr 04 02:58 PM
10X Fund, L.P.10% OwnerFeb 02Sale2.1010,00021,0006,178,940Feb 04 06:23 PM
Schwartz Elissa J.DirectorJan 21Buy2.001,0002,0001,000Jan 24 08:42 AM
FREEMAN KEVIN DDirectorJan 19Buy1.965,0009,80650,000Jan 19 11:02 AM
Zordani Richard A. Jr.DirectorJan 14Buy2.025,00010,10019,583Jan 18 08:54 AM
10X Fund, L.P.10% OwnerJan 11Sale2.1010,00021,0006,188,940Jan 13 03:42 PM
FREEMAN KEVIN DDirectorDec 06Buy2.285,00011,40050,000Dec 15 04:25 PM
FREEMAN KEVIN DDirectorDec 06Buy2.345,00011,70045,000Dec 06 02:09 PM
10X Fund, L.P.10% OwnerDec 02Sale2.3710,00023,7006,198,940Dec 06 12:42 PM
10X Fund, L.P.10% OwnerNov 01Sale3.1910,00031,9006,208,940Nov 04 11:55 AM
FREEMAN KEVIN DDirectorOct 29Buy3.172,0006,34040,000Nov 01 12:51 PM
FREEMAN KEVIN DDirectorOct 21Buy3.192,0006,38038,000Oct 21 12:52 PM
FREEMAN KEVIN DDirectorOct 19Buy3.373,00010,10736,000Oct 19 02:14 PM
10X Fund, L.P.10% OwnerOct 15Sale3.3710,00033,7006,218,940Oct 19 03:18 PM
10X Fund, L.P.10% OwnerOct 04Sale3.6210,00036,2006,228,940Oct 06 12:00 PM
FREEMAN KEVIN DDirectorSep 23Buy3.883,00011,63133,000Sep 23 04:14 PM
10X Fund, L.P.10% OwnerSep 01Sale3.9110,00039,1006,238,940Sep 03 09:00 AM
10X Fund, L.P.10% OwnerAug 02Sale3.2510,00032,5006,248,940Aug 03 03:48 PM
10X Fund, L.P.10% OwnerJul 09Sale3.5410,00035,4006,258,940Jul 15 02:27 PM
10X Fund, L.P.10% OwnerJun 01Sale3.9110,00039,1006,268,940Jun 03 05:27 PM